EDIT vs CRSP
EDIT and CRSP side by side — valuation & fundamentals (public data).
Key statistics
| Metric | EDITEditas Medicine, Inc. | CRSPCRISPR THERAPEUTICS AG |
|---|---|---|
| Market cap | $258.47M | $4.79B |
| P/S | 6.4x | 1365.3x |
| Revenue growth (YoY) | 25.4% | -90.6% |
| Earnings growth (YoY) | 32.5% | -58.8% |
| EBIT margin | -394.9% | -18933.6% |
| ROE | -3631.1% | -33.3% |
| ROIC | — | -32.6% |
| 1y total return | +8.0% | -11.7% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: EDIT vs CRSP
| Metric | EDIT | CRSP |
|---|---|---|
| End value | $1.9K | $35.2K |
| Total return | -81.0% | +251.8% |
| CAGR | -15.6% | +13.7% |
| Volatility | 84.4% | 64.1% |
| Sharpe | 0.16 | 0.46 |
| Sortino | 0.25 | 0.71 |
| Max drawdown | -98.9% | -85.1% |
Based on 2459 common trading days, 2016-10-19 → 2026-08-03 · risk-free 3.91% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)